NBIX

NASD Neurocrine Biosciences, Inc.
Oct 5, 2026 · 6:15 AM ET LAST TRADE Market Closed

$143.09 ↓ -0.09 (-0.06%) Trading Down from the previous close of $143.18

YTD change
+0.89%
vs 20-day SMA
-2.69%
vs 200-day SMA
-2.84%

Price ranges

Previous day
$140.36 $144.56
open $141.41 close $143.18
+$1.77 (+1.25%)
Today
$0.00 $0.00
$143.09
Past week
$136.31 $144.56
from $138.40 now $143.09
+$4.69 (+3.39%)
Past month
$136.31 $159.94
from $158.35 now $143.09
-$15.26 (-9.64%)
This year
$122.14 $186.12
from $141.83 now $143.09
+$1.26 (+0.89%)

Price & Performance

+10.70 (+8.08%) / 6M

$121.59$144.47$167.35$190.23Apr 6Jul 6Oct 2

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Neutral
  • The stock is 23.1% away from all-time highs of $186.12
  • NBIX is up 1% since the beginning of the year
  • NBIX is up 4% over the past 12 months
  • NBIX is down 10% over the past 1 month
  • 5% of all NBIX investors are betting against NBIX

NBIX reads neutral: price sits below both the 20- and 200-day averages, the 12-month move is +2.7%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable Yes
EPS $1.39
Earnings momentum +27.5% Quarterly EPS growth
Quarterly change +27.5%

Valuation

P/E ratio 20.63
Enterprise value $14.9B
Beta 0.71

Balance sheet & scale

Income$705.5K
Revenue$3.4B
Cash$389.8M
Debt$401.8K
Income / Debt 1.76×

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Manufacturing
Sub Sector Chemical Manufacturing
Market cap $14.5B

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Competitor comparison

TickerCompany PriceChange
CMXHF CSL Limited $127.50 +0.11%
ARGX argenx SE Sponsored ADR $919.21 -1.79%
ONC BeOne Medicines Ltd. Sponsored ADR $358.07 -0.20%
WXXWY WuXi Biologics (Cayman) Inc. Unsponsored ADR $13.95 -2.45%
INCY Incyte Corporation $115.30 -1.57%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.